Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FALCHERO, Lionel
API-CAT, NCT03692065 / 2017-003342-25: STUDY for APIxaban Cancer Associated Thrombosis	Completed	3	1766	Europe, Canada	Apixaban 5 MG, Apixaban 2.5 MG	Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb	Cancer-associated Thrombosis	09/24	10/24
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax	Recruiting	2	100	Europe	Durvalumab	UNICANCER, AstraZeneca	Small Cell Lung Carcinoma	02/28	02/30
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC	Active, not recruiting	N/A	413	Europe	Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)	Groupe Francais De Pneumo-Cancerologie, AstraZeneca	Non-Small Cell Lung Cancer	06/27	06/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FALCHERO, Lionel
API-CAT, NCT03692065 / 2017-003342-25: STUDY for APIxaban Cancer Associated Thrombosis	Completed	3	1766	Europe, Canada	Apixaban 5 MG, Apixaban 2.5 MG	Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb	Cancer-associated Thrombosis	09/24	10/24
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax	Recruiting	2	100	Europe	Durvalumab	UNICANCER, AstraZeneca	Small Cell Lung Carcinoma	02/28	02/30
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC	Active, not recruiting	N/A	413	Europe	Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)	Groupe Francais De Pneumo-Cancerologie, AstraZeneca	Non-Small Cell Lung Cancer	06/27	06/27